Chronic myeloid leukaemia

References 

1. Goldman JM, Melo JV. Chronic myeloid leukaemia. N Engl J Med. 2003;349:1449–1462
2. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose Ara-C for newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
   • CrossRef
3. Druker BJ, Guilhot F, O’Brien SG, et al. Five year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemia. New Engl J Med. 2006;355:2408–2417
4. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828–2935
   • CrossRef
5. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-Net. Blood. 2006;108:1809–1820
   • MEDLINE
   • CrossRef
6. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med. 2003;349:1421–1430
7. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37
   • MEDLINE
   • CrossRef
8. Chronic Myeloid Leukemia Trialists Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616–1620
   • MEDLINE
   • CrossRef
9. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087–1092
   • Abstract
   • Full Text
   • Full-Text PDF (85 KB)
   • CrossRef
10. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good risk’ chronic granulocytic leukemia. Blood. 1984;63:789–799
    • MEDLINE